Overview

Charles River offers a broad range of syngeneic tumor models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1 and anti-CTLA-4), making us the ideal partner to advance your immuno-oncology pipeline.

Models With Profile

HistotypeCell Line
BladderMBT-2
BrainGL261
Breast4T1, EMT-6
ColonColon26, CT26, MC38
LungKLN 205, Lewis Lung, Madison109
LymphomaA20, E.G7-OVA
MelanomaB16F10, CloudmanS91
PancreaticPan02
RenalRenca

Models Without Profile*

HistotypeCell Line
BreastEMT-6-BRCA1(−/−), EMT-6-BRCA1(+/−), 4T1-BRCA1(+/−)
HepatomaYoshida
LeukemiaC1498, L1210, P388
LymphomaEL4
MastocytomaP815
PlasmacytomaJ558
SarcomaEHS

*Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.

SYNGENEIC MODEL DATA
cancer cell dividing

Access our syngeneic model data including check point inhibitor and whole exome sequencing (WES).

Download now